Cancer Statistics Center

https://cancerstatisticscenter.cancer.org/

Last activity: 24.09.2026

Active

Mentions

Mentions in press and media 22

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Nov 7, 2023	Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial	SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and ...
Oct 3, 2023	First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial	SYDNEY, Oct. 3, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and ...
Jun 20, 2023	Clarity commences COMBAT theranostic prostate cancer trial in the US	SYDNEY, June 20, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and...
Nov 14, 2022	TriSalus Life Sciences to Become Publicly Traded Through Merger with MedTech Acquisition Corporation	Oncology Therapeutics Company Focused on Transforming Cancer Treatment with Proprietary Innovative Therapies and Disruptive Delivery Technology
Oct 29, 2022	California cancer care isn’t equitable; a new law might help	In summary Low-income patients who need specialized cancer treatment often struggle to get it. Advocates say a new law is a small step toward improving services for those patients. Cancer is the second leading cause of death in California, ...
Jul 20, 2022	Recruitment complete for Clarity's PROPELLER prostate cancer diagnostic trial	SYDNEY, July 20, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announc...
Mar 28, 2022	Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment	SYDNEY, March 28, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announ...
Mar 24, 2022	New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer	SYDNEY, March 24, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announ...
Feb 7, 2022	US FDA Study May Proceed letter for Clarity's Cu-64 SAR-bisPSMA trial in prostate cancer	SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce...
Dec 1, 2021	Fifty percent recruitment milestone for PROPELLER prostate cancer trial	SYDNEY, Dec. 1, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce...
Nov 10, 2021	Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed	Clarity Pharmaceuticals completes recruitment for the initial dosimetry phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCT) in patients with metastatic castrate-resist...
Aug 25, 2021	First patient treated in Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial	SYDNEY, Aug. 25, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or the "Company"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the gro...
Jul 28, 2021	Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial	SYDNEY, July 28, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has commenced its 64/67Cu SAR-bisPSMA theranostic clinic...
Jul 2, 2021	Jazz Pharmaceuticals : Announces U.S. FDA Approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (Form 8-K)	Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Approval under U.S. FDA's Real-Time Oncology Revi...
Jun 1, 2021	Janssen Pharmaceuticals : Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma	News Release Media Contacts: Brian Kenney Phone: +1 215-620-0111 Satu Glawe Phone: +49 172-294 6264 Investor Relations: Jennifer McIntyre Office: +1 732-524-3922 U.S. Medical Inquiries: +1 800-526-7736 Janssen Announces U.S. FDA Breakthroug...
May 4, 2021	Clarity receives US FDA clearance of IND Application for its next-generation PSMA theranostic products	SYDNEY, May 4, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has received a response from the U.S. Food and Drug Admini...
Sep 17, 2018	NYU applies open source Google AI to diagnose lung cancer	Did you miss a session from GamesBeat Summit 2022? All sessions are available to stream now. Learn more. If recent research is any indication, artificial intelligence (AI) has a bright future in medicine. Nvidia developed an AI system that ...
Jul 25, 2018	De-intensifying treatment for early thyroid cancer	How much thyroid gland is enough? Can you get by with half of one? That question is relevant to the more than 50,000 Americans diagnosed with thyroid cancer each year. As we point out in a study published Wednesday in the New England Journa...
Sep 14, 2016	Men with early prostate cancer can safely opt out of treatment, finds landmark study	Men diagnosed with early prostate cancer can safely choose active monitoring rather than surgery or radiation without cutting their lives short, according to an eagerly awaited landmark study published on Wednesday. Although research dating...
Jun 15, 2016	4 things to know about the new colorectal cancer screening advice	The latest recommendations on screening for colorectal cancer, released on Wednesday, include some new bits: You can have a virtual colonoscopy (no huge tube snaking its way up your insides), even 85-year-olds might benefit from being scree...
	Four innovations that may shape cancer treatment	While significant progress has been made in the treatment of cancer, there is still a long way to go. Cancer has been the second leading cause of death among Americans for almost a decade.1 This year in the United States alone, it is estima...

Reviews 0

FAQ about Cancer Statistics Center

What has the press written about Cancer Statistics Center?

Parsers VC has collected 22 articles mentioning Cancer Statistics Center, among them “Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial” (Nov 7, 2023) and “First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial” (Oct 3, 2023).

Is Cancer Statistics Center still active?

Yes, Cancer Statistics Center is active; its latest activity on Parsers VC dates from Sep 24, 2026.